Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide?
Hellmich
B
B
Poliklinik für Rheumatologie, Universitätsklinkum Schleswig-Holstein, Lübeck, Germany. bernhard.helllmich@rheuma.uni-luebeck.de
Kausch
I
I
Doehn
C
C
Jocham
D
D
Holl-Ulrich
K
K
Gross
W L
WL
D003520:Cyclophosphamide / Q000009:adverse effects*; D014890:Granulomatosis with Polyangiitis / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015080:Mesna / Q000627:therapeutic use; D020011:Protective Agents / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000209:etiology* / Q000517:prevention & control
D007166:Immunosuppressive Agents; D020011:Protective Agents; D003520:Cyclophosphamide; D015080:Mesna